has knowledgeable contact person
uses biomaterial
Datasets  >  clinical study dataset  >  HSV-based vectors optimised...

HSV-based vectors optimised for antigen delivery to dendritic cells by the deletion of HSV genes

clinical study dataset

First clinical vaccination data has been obtained using an HSV vector expressing full length tyrosinase, gp100 and MART-1 to transduce DC from melanoma patients.

Biovex has developed HSV-based vectors optimised for antigen delivery to dendritic cells by the deletion of HSV genes which usually inhibit DC function. These deliver antigens to DC at very high efficiency and activate the transduced cells similarly to LPS. Based on this technology, Biovex began a clinical program where an HSV vector expressing full length tyrosinase, gp100 and MART-1 was used to transduce DC from melanoma patients which were then to be used for vaccination. Due to a change in emphasis, Biovex is no longer progressing this program but has, as a result, considerable internal expertise, reagents and methodology which could be of use to the project if partners would like to use HSV-based technology for the delivery of antigens to DC. This includes the vectors themselves, and the shuttle plasmids into which antigens are inserted and provides the possibility of using these vectors for a variety of pre-clinical, and ultimately clinical studies.







created over 14 years ago (2 March 2009)    last modified over 11 years ago (14 October 2011)   [ RDF Rdf ]   [ RelFinder Relfinder ]